SECUKINUMAB SIGNFICANTLY IMPROVES THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN PATIENTS PREVIOUSLY EXPOSED TO ANTI-TUMOUR NECROSIS FACTOR THERAPY AND ANTI-TUMOUR NECROSIS FACTOR-NAIVE PATIENTS: 52 WEEK RESULTS FROM THE PHASE III FUTURE 2 TRIAL

被引：0
作者：
McInnes, Iain [1 ]
Chinoy, Hector [2 ]
Kavanaugh, Arthur [3 ]
Wang, Zailong [4 ]
Mpofu, Shephard [5 ]
机构：
[1] Univ Glasgow, Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[2] Univ Manchester, Musculoskeletal Res Inflammat & Repair, Manchester, Lancs, England
[3] Univ Calif San Diego, Sch Med, Innovat Therapy, San Diego, CA 92103 USA
[4] Nova Pharmaceut Corp, Stat, E Hanover, NJ USA
[5] Novartis Pharmaceut, Clin Dev, Basel, Switzerland
来源：
RHEUMATOLOGY | 2016年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
195
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [41] Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
    R Russo
    M Katsicas
    Pediatric Rheumatology, 9 (Suppl 1)
  • [42] Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients
    Peer, Faseeha C.
    Miller, Andrew
    Pavli, Paul
    Subramaniam, Kavitha
    INTERNAL MEDICINE JOURNAL, 2017, 47 (12) : 1445 - 1448
  • [43] The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease
    Shale, Matthew J.
    BRITISH MEDICAL BULLETIN, 2009, 92 (01) : 61 - 77
  • [44] Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases
    Bank, Steffen
    Andersen, Paal Skytt
    Burisch, Johan
    Pedersen, Natalia
    Roug, Stine
    Galsgaard, Julie
    Turino, Stine Ydegaard
    Brodersen, Jacob Broder
    Rashid, Shaista
    Avlund, Sara
    Olesen, Thomas Bastholm
    Green, Anders
    Hoffmann, Hans Jurgen
    Thomsen, Marianne Kragh
    Thomsen, Vibeke Ostergaard
    Nexo, Bjorn Andersen
    Vogel, Ulla
    Andersen, Vibeke
    DANISH MEDICAL JOURNAL, 2015, 62 (03):
  • [45] AUDIT OF ANTI-TUMOUR NECROSIS FACTOR THERAPY IN CROHN'S DISEASE: BETTER RESULTS IN PATIENTS WITH NO PREVIOUS SURGERY
    Patel, R. N.
    Gregg, B.
    Kneebone, A.
    Leiper, K. P.
    Ellis, A.
    Watson, A. J.
    Rhodes, J. M.
    GUT, 2009, 58 : A99 - A100
  • [46] Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    Darren M Ashcroft
    Kath D Watson
    Kimme L Hyrich
    Peter R Noyce
    Deborah PM Symmons
    Arthritis Research & Therapy, 11
  • [47] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM AN INTERNATIONAL PHASE 3 TRIAL
    Kavanaugh, Arthur
    Kivitz, Alan
    McInnes, Iain B.
    Mease, Philip
    Mpofu, Shephard
    Wang, Zailong
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 141 - 142
  • [48] Varicella-zoster virus infection in rheumatoid arthritis patients in the anti-tumour necrosis factor era
    Cacciapaglia, F.
    Zuccaro, C.
    Iannone, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (06) : 917 - 923
  • [49] Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Saad, Amr A.
    Ashcroft, Darren M.
    Watson, Kath D.
    Hyrich, Kimme L.
    Noyce, Peter R.
    Symmons, Deborah P. M.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
  • [50] Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
    I Cavazzana
    F Franceschini
    E Danieli
    P Airò
    R Cattaneo
    Arthritis Research & Therapy, 7
12345